Magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment

Avinash Chandra, George Dervenoulas, Marios Politis*, Alzheimer's Disease Neuroimaging Initiative

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

203 Citations (Scopus)


Research utilizing magnetic resonance imaging (MRI) has been crucial to the understanding of the neuropathological mechanisms behind and clinical identification of Alzheimer’s disease (AD) and mild cognitive impairment (MCI). MRI modalities show patterns of brain damage that discriminate AD from other brain illnesses and brain abnormalities that are associated with risk of conversion to AD from MCI and other behavioural outcomes. This review discusses the application of various MRI techniques to and their clinical usefulness in AD and MCI. MRI modalities covered include structural MRI, diffusion tensor imaging (DTI), arterial spin labelling (ASL), magnetic resonance spectroscopy (MRS), and functional MRI (fMRI). There is much evidence supporting the validity of MRI as a biomarker for these disorders; however, only traditional structural imaging is currently recommended for routine use in clinical settings. Future research is needed to warrant the inclusion for more advanced MRI methodology in forthcoming revisions to diagnostic criteria for AD and MCI.

Original languageEnglish
JournalJournal of Neurology
Early online date17 Aug 2018
Publication statusE-pub ahead of print - 17 Aug 2018


  • Alzheimer’s disease
  • Magnetic resonance imaging
  • Mild cognitive impairment
  • Neuropathology


Dive into the research topics of 'Magnetic resonance imaging in Alzheimer’s disease and mild cognitive impairment'. Together they form a unique fingerprint.

Cite this